Low follicle stimulating hormone

If there is a problem with the follicle-stimulating hormone, it should be paid attention to. If it is not improved in time, conception will fail or even ectopic pregnancy will occur, which will seriously endanger the health of women. Therefore, the only way is to use injections to increase the follicle-stimulating hormone index to prevent it from being too low again and causing more serious consequences.

Local reactions at the injection site, fever, joint pain, gastrointestinal symptoms, and pelvic or breast pain may occur. Mild to moderate ovarian enlargement and sometimes ovarian cysts may occur. Severe ovarian hyperstimulation syndrome is less common. In some rare cases, arterial thromboembolism has occurred. Its occurrence is related to the use of HMG and HCG treatment, and it may also occur during treatment with this drug Profasi. In a few cases, multiple fetuses may occur after treatment with Profasi, most of which are twins. In in vitro fertilization, this phenomenon is related to the number of embryo replications. The incidence of pregnancy loss due to abortion or miscarriage is similar to that due to other fertility problems, and an ectopic pregnancy is more likely to occur if there is a history of ureteral disease.

Adhere to the recommended treatment dose and monitor the treatment regimen to reduce the occurrence of ovarian hyperstimulation syndrome. In clinical verification, the incidence of severe ovarian hyperstimulation syndrome is less than 1%. The use of this drug to treat excessive ovarian response generally does not induce significant adverse reactions unless HCG is used to induce ovulation or pregnancy has occurred. Ovarian hyperstimulation syndrome usually occurs 1-2 weeks after HCG treatment or ovulation.

If symptoms such as pelvic pain, abdominal distension, or ovarian enlargement occur, or if estrogen measurement or ultrasound examination indicates an excessive estrogen response, treatment should be discontinued and HCG treatment should be discontinued, and sexual intercourse should be avoided to prevent ovarian hyperstimulation. Symptoms such as ascites, pericardial effusion, pleural effusion, hemoconcentration, secondary aldosteronism, or hypercoagulable state may occur. These symptoms should be managed with appropriate medical care, including avoiding unnecessary pelvic examinations, and usually resolve on their own after the onset of menstruation if pregnancy does not occur. Patients with a history of lactose allergy must take into account that this medicine contains lactose.